Skip to main content

Table 4 Availability of interventions for PPH treatment bundle: % (95% CI)

From: Scaling up interventions: findings and lessons learned from an external evaluation of Niger’s National Initiative to reduce postpartum hemorrhage

 

Phase 1 (n = 69)

Phase 2 (n = 69)

p-value

Step 1: Misoprostol – treatment doses

Received at least 1 procurement of misoprostol treatment doses

72.8 (55.5, 91.2)

75.3 (52.1, 89.5)

P = .78

Experienced stock out within the last 12 months

24.7 (9.4, 50.8)

53.4 (33.1, 72.6)

P = .06

Stock-out levels within last 12 months

 Never

75.3 (49.2, 90.6)

47.2 (27.7, 67.7)

P = .07

 Less than 1 month

5.4 (1.5, 17.2)

26.6 (12.0, 49.2)

 1–3 months

10.4 (2.6, 33.1)

26.1 (10.6, 51.3)

 Over 3 months

8.9 (1.2, 44.1)

0

Expired stock at time of data collection

25.2 (11.9, 45.9)

49.8 (33.3, 66.4)

P = .05

Step 2: Uterine balloon tamponade kits

Received at least 1 procurement of UBT kits

80 (61.5, 91.0)

80 (57.0, 92.0)

p = .63

Experienced stock-out within the last 12 months

0.3 (0, 2.7)

23.4 (10.1, 45.4)

p < .001

Stock-out levels within last 12 months

 Never

99.7 (97.3, 100)

81.8 (59.4, 93.2)

p = .001

 Less than 1 month

0

2.1 (0.4, 9.3)

 1–3 months

0.3 (0, 2.7)

16.1 (5.3, 39.9)

 Over 3 months

0

0

Incomplete UBT kits in stock

9.6 (3.8, 22.3)

60.1 (41.2, 76.4)

p < .001

Step 3: Non-pneumatic anti-shock garment

Functional NASG in stock

87.9 (63.3, 96.4)

91.5 (66.7, 98.3)

p = .62

Quantity of NASG in stock

 None

12.1 (3.6, 33.7)

8.5 (1.7, 33.3)

p = .62

 1–3

87.5 (66.3, 96.1)

91.1 (67.2, 98.1)

 4+

0.4 (0.2, 1.1)

0.4 (0.2, 1.0)